Similar articles

• [Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].

  Tokunaga K, Takahashi S. Tokunaga K, et al. Nihon Rinsho. 2002 Feb;60 Suppl 2:445-8. Nihon Rinsho. 2002. PMID: 11979824 Review. Japanese. No abstract available.
• [PPI plus bismuth-based quintuple therapy].

  Kimura K, Hiratsuka T, Tamura K, Hiratsuka H, Suzuki T, Bray R. Kimura K, et al. Nihon Rinsho. 2005 Nov;63 Suppl 11:452-8. Nihon Rinsho. 2005. PMID: 16363577 Clinical Trial. Japanese. No abstract available.
• [Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].

  Kobayashi K, Fujishiro M, Omata M, Oka M. Kobayashi K, et al. Nihon Rinsho. 2005 Nov;63 Suppl 11:459-60. Nihon Rinsho. 2005. PMID: 16363578 Review. Japanese. No abstract available.
• [Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].

  Fujioka T. Fujioka T. Nihon Rinsho. 2005 Nov;63 Suppl 11:27-30. Nihon Rinsho. 2005. PMID: 16363499 Review. Japanese. No abstract available.
• [Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].

  Inoue K, Sugano K. Inoue K, et al. Nihon Rinsho. 2002 Feb;60 Suppl 2:460-4. Nihon Rinsho. 2002. PMID: 11979828 Review. Japanese. No abstract available.